SLC5A2 and myocardial infarction: Similarly, in the study by Zhou et al in a Chinese population, those treated with SGLT2 inhibitors had a 27% lower risk of developing new‐onset heart failure, as well as reductions in the risk of all‐cause mortality and myocardial infarction.16